Dr. Reddy’s Laboratories gets Health Canada nod for generic Semaglutide injection
Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, becoming the first company approved for the product in Canada ahead of the scheduled review date. The approval includes two dosage strengths: 2 mg/pen and 4 mg/pen, both at a concentration of 1.34 mg/mL. Canada is the second-largest market globally for Semaglutide, according to IQVIA data cited by the company.
Opening excerpt (first ~120 words) tap to expand
Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.It has become the first company to receive the market authorisation for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The authorisation covers the 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).Canada is recognised as the world’s second-largest market for Semaglutide, Dr. Reddy’s said, citing IQVIA MAT Q3 2025 numbers.
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
